SCHEMBL1157554

SCHEMBL1157554

COc1ccc(N(Cc2cccnc2)c2cccc(NS(=O)(=O)Cc3ccccc3)c2)cc1OC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 14/20 0.56
PDE4D Q08499 6/20 0.55
PDE4B Q07343 5/20 0.55
PDE4C Q08493 5/20 0.55
GRM2 Q14416 3/20 0.43
CYP17A1 P05093 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1157651 0.93 PDE4A (0.57) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL6954189 0.91 PDE4A (0.55) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL6948587 0.89 PDE4A (0.53) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL1157950 0.86 PDE4A (0.59) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL1157497 0.86 PDE4A (0.62) PDE4APDE4DPDE4BPDE4C
SCHEMBL1157859 0.85 PDE4A (0.60) PDE4APDE4DPDE4BPDE4C
SCHEMBL1157400 0.85 PDE4A (0.61) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL1158003 0.85 PDE4A (0.61) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL6952831 0.84 PDE4A (0.56) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL1157594 0.84 PDE4A (0.53) PDE4APDE4DPDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699890-B2 N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES MEMORY PHARMACEUTICALS CORP. 2004-03-02 US claimed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 US claimed
US-20110046146-A9 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2011-02-24 US disclosed
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
US-7205320-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-17 US disclosed
US-20070078139-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2007-04-05 US disclosed
US-20040230072-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A (US) 2004-11-18 US disclosed
US-6699890-B2 N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES MEMORY PHARMACEUTICALS CORP. 2004-03-02 US disclosed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 US disclosed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149052-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4D 9/4885PDE4B 2/4885
US-20020151566-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4D 9/4885PDE4B 2/4885
US-20040230072-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4D 9/4885PDE4B 2/4885
US-20110046146-A9 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B PDE4A 1/4885PDE4D 9/4885PDE4B 2/4885
US-20070078139-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B PDE4A 1/4885PDE4D 9/4885PDE4B 2/4885
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4D 8/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.